At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
Sitagliptindrug
Likely dose
Sitagliptin 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mechanism of Reduced Response to DPP-4 Inhibitor in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 4 clinical trial evaluating Sitagliptin for Type 2 Diabetes Mellitus. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4 inhibitor
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesSouth Korea
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 2011
Enrollment StartDec 2011
Primary CompletionAug 2014
Study CompletionJul 2015
TodayJul 2026
First PostedOct 10, 2011
Enrollment StartDec 1, 2011
Primary CompletionAug 1, 2014
Study CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 14.7 years ago
Interventions
Sitagliptindrug
Sitagliptin (100mg, per oral) once a day.